The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

By M. Hidalgo, E. Rowinsky. Oncogene, 2000

616 citations recorded by the source corpus.

Subfields: Ecology, Evolution, Behavior and Systematics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/be35efe232f6c79b8861e43d235326db7a31a29f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Ecology, Evolution, Behavior and Systematics

J. Blenis

In Molecular Biology

Citations in the corpus

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. (2002, background): “…drug that is currently used to block immune rejec-New York, New York 10021 tion of transplanted organs (Saunders et al., 2001) and in trials for the treatment of cancer (Dudkin et al., 2001; Hidalgo and Rowinsky, 2000) and for the prevention of restenosis after angioplasty (Sousa et al., 2001).”
Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. (2002, background): “Rapamycin treatment decreases colony formation by myrPI3K and myrAkt transformed fibroblasts and has been shown to have activity against PTEN-deficient tumors (Hidalgo and Rowinsky, 2000; Aoki et al., 2001; Neshat et al., 2001; Podsypanina et al., 2001).”
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism (2007, background): “E-mail: xiaolinw@mail.nih.gov Oncogene (2007) 26, 1932–1940 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc currently being studied in the clinic for the treatment of a variety of tumor types (Hidalgo and Rowinsky, 2000; Huang and Houghton, 2003).”
eIF-4E expression and its role in malignancies and metastases (2004, background): “Early phase clinical trials with the rapamycin derivative, CCI-779, have indicated that this approach may indeed be a promising therapy, even as a single agent, for cancer treatment (Hidalgo and Rowinsky, 2000; Peralba et al., 2003).”
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression (2004, background): “…such as CCI-779 and RAD001, are currently being tested in clinical trials for efficacy against a variety of human tumors (reviewed in Elit, 2002; Hidalgo and Rowinsky, 2000; Huang and Houghton, 2003) In addition to being a promising*Correspondence: J Blenis, E-mail:…”
Activation of the PI3K/Akt pathway and chemotherapeutic resistance. (2002, background): “In animal models, treatment with rapamycin also produced a profound antiproliferative effect in several tumor types (Hidalgo and Rowinsky, 2000; Seufferlein and Rozengurt, 1996).”